Literature DB >> 8917265

Smoking and prognosis after acute myocardial infarction in the thrombolytic era (Israeli Thrombolytic National Survey).

S Gottlieb1, V Boyko, D Zahger, J Balkin, H Hod, B Pelled, S Stern, S Behar.   

Abstract

OBJECTIVES: This study sought to compare the relation between smoking and the 30-day and 6-month outcome after acute myocardial infarction in an Israeli nationwide survey.
BACKGROUND: Studies before and during the thrombolytic era reported similar or lower early mortality after acute myocardial infarction in smokers than in nonsmokers. This finding is intriguing and may be misleading because numerous epidemiologic studies have clearly shown that smoking is an independent risk factor for atherosclerosis, myocardial infarction and death.
METHODS: The study cohort comprised 999 consecutive patients with an acute myocardial infarction from a prospective nationwide survey conducted during January and February 1994 in all coronary care units operating in Israel. The prognosis of 367 patients (37%) who were smokers (current smokers and those who smoked up to 1 month before admission) was compared with that of 632 nonsmokers (past smokers or those who never smoked).
RESULTS: Smokers were on average 10 years younger and were more frequently men and patients with a family history of coronary heart disease and inferior infarction and less frequently patients with a previous infarction or a history of angina, hypertension and diabetes than nonsmokers. Smokers also had a lower incidence of congestive heart failure on admission or during the hospital period. Thrombolytic therapy (49% vs. 40%, p < 0.01) and aspirin (89% vs. 80%, p < 0.001) were administered more frequently in smokers than nonsmokers. The crude 30-day (6.0% vs. 15.7%) and cumulative 6-month (7.9% vs. 21.5%) mortality rates were significantly lower (p < 0.0001 for both) in smokers than nonsmokers, respectively. However, after adjustment for age, baseline characteristics, thrombolytic therapy and invasive coronary procedures, the lower 30-day (odds ratio [OR] 0.75, 95% confidence interval [CI] 0.43 to 1.29, p = 0.30) and 6-month (hazard ratio 0.84, 95% CI 0.54 to 1.30, p = 0.42) mortality rates in smokers and nonsmokers were not significantly different. The model had a power of 0.80 for OR 0.50, with alpha 0.1.
CONCLUSIONS: In our nationwide survey, the seemingly better prognosis of smokers early after acute myocardial infarction was no longer evident after adjustment for baseline and clinical variables and may be explained by their younger age and a more favorable risk profile. Smokers develop acute myocardial infarction a decade earlier than nonsmokers. Efforts to lower the prevalence of smoking should continue.

Entities:  

Mesh:

Year:  1996        PMID: 8917265     DOI: 10.1016/s0735-1097(96)00334-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  16 in total

1.  Cumulative burden of atherosclerotic risk genotypes and the age at onset of a first myocardial infarction: a case-only carriership approach.

Authors:  Ilan Goldenberg; Arthur J Moss; Daniel Ryan; Grzegorz Pietrasik; Wojciech Zareba; Scott McNitt; Shirley W Eberly
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-07       Impact factor: 1.468

2.  Impact of smoking status on cardiovascular outcomes following percutaneous coronary intervention.

Authors:  Burhan Mohamedali; Adhir Shroff
Journal:  Clin Cardiol       Date:  2013-05-13       Impact factor: 2.882

3.  Effect of smoking on clinical outcomes in patients receiving rotational atherectomy in calcified coronary lesions: from the ROCK Registry, South Korea.

Authors:  Won Young Jang; Su Nam Lee; Sung-Ho Her; Donggyu Moon; Keon-Woong Moon; Ki-Dong Yoo; Kyusup Lee; Ik Jun Choi; Jae Hwan Lee; Jang Hoon Lee; Sang Rok Lee; Seung-Wan Lee; Kyeong Ho Yun; Hyun-Jong Lee
Journal:  Ann Saudi Med       Date:  2021-08-22       Impact factor: 1.526

4.  Smoking, clopidogrel, and mortality in patients with established cardiovascular disease.

Authors:  Jeffrey S Berger; Deepak L Bhatt; Steven R Steinhubl; Mingyuan Shao; P Gabriel Steg; Gilles Montalescot; Werner Hacke; Keith A Fox; A Michael Lincoff; Eric J Topol; Peter B Berger
Journal:  Circulation       Date:  2009-11-23       Impact factor: 29.690

5.  The smoker's paradox: insights from the angiographic substudies of the TIMI trials.

Authors:  Brad G Angeja; Sarah Kermgard; Michael S Chen; Matthew McKay; Sabina A Murphy; Elliott M Antman; Christopher P Cannon; Eugene Braunwald; C Michael Gibson
Journal:  J Thromb Thrombolysis       Date:  2002-06       Impact factor: 2.300

Review 6.  The "smoker's paradox" in patients with acute coronary syndrome: a systematic review.

Authors:  Erlend Aune; Jo Røislien; Mariann Mathisen; Dag S Thelle; Jan Erik Otterstad
Journal:  BMC Med       Date:  2011-08-23       Impact factor: 8.775

7.  Influence of smoking on the location of acute myocardial infarctions.

Authors:  Rahel Alemu; Eileen E Fuller; John F Harper; Mark Feldman
Journal:  ISRN Cardiol       Date:  2011-04-17

8.  Risk factors for long-term outcome of drug-eluting stenting in adults with early-onset coronary artery disease.

Authors:  Guipeng An; Zhongqi Du; Xiao Meng; Tao Guo; Guishuang Li; Yuguo Chen; Jifu Li; Fengshuang An; Yun Zhang; Wenjing Li; Cheng Zhang
Journal:  Int J Med Sci       Date:  2014-05-10       Impact factor: 3.738

9.  Smoker's Paradox in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Tanush Gupta; Dhaval Kolte; Sahil Khera; Prakash Harikrishnan; Marjan Mujib; Wilbert S Aronow; Diwakar Jain; Ali Ahmed; Howard A Cooper; William H Frishman; Deepak L Bhatt; Gregg C Fonarow; Julio A Panza
Journal:  J Am Heart Assoc       Date:  2016-04-22       Impact factor: 5.501

10.  Paradoxical association of smoking with in-hospital mortality among patients admitted with acute ischemic stroke.

Authors:  Syed F Ali; Eric E Smith; Deepak L Bhatt; Gregg C Fonarow; Lee H Schwamm
Journal:  J Am Heart Assoc       Date:  2013-06-19       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.